|
|
基于二硫化相关lncRNA构建肝细胞癌预后模型
|
Abstract:
背景：二硫化血症是一种新的代谢调节性细胞死亡，其特征是异常的二硫化物应激和肌动蛋白网络崩溃。然而，二硫化相关lncRNAs在肝细胞癌(HCC)中的预测潜力仍在研究之中。研究方法：采用皮尔逊相关分析、单变量分析、最小绝对缩减和选择算子分析等方法获得二硫化相关lncRNA，并进行多变量Cox回归分析，构建二硫化相关lncRNA模型。此外，我们还通过共识聚类分析将HCC患者分为亚型，进一步研究了免疫微环境的差异，检查了免疫检查点，评估了免疫状态，确定了潜在的疾病治疗药物，为HCC治疗提供了新的思路和选择。研究结果：共获得了4个与二硫化相关的lncRNAs (GIHCG, MKLN1-AS, AL031985.3, AL442125.2)，并建立了预后模型，我们发现高风险组患者的总生存率(OS)更低，ssGSEA分析显示免疫细胞浸润与风险评分呈正相关。低危患者对吉非替尼敏感，高危患者对博来霉素、吉西他滨、顺铂和依托泊苷敏感。聚类分析确定了两种不同的亚型，它们具有不同的预后和免疫浸润。这有助于我们为HCC患者确定更精确的靶向疗法。结论：我们建立了一个与二硫化相关的lncRNA模型，该模型可用于预测HCC患者的预后、肿瘤突变负荷、免疫细胞浸润情况以及对药物治疗的反应。
Background: Disulfidptosis is a novel metabolically regulated cell death characterized by aberrant disulfide stress and actin network collapse. However, the predictive potential of disulfidptosis-related lncRNAs in hepatocellular carcinoma (HCC) is still under investigation. Methods: Pearson correlation analysis, univariate analysis, least absolute shrinkage, and selection operator analysis were used to obtain disulfidptosis-related lncRNAs, and conducted multivariate Cox regression analysis to construct a model of disulfidptosis-related lncRNAs. The correlation between risk score and pathway enrichment analysis, immune infiltrating cells, immune checkpoint genes, and anticancer drug sensitivity was analyzed. In addition, we classified HCC patients into subtypes by consensus clustering analysis, further investigated the differences in the immune microenvironment, examined immune checkpoints, assessed immune status, identified potential disease therapeutic drugs, and provided new ideas and options for HCC treatment. Results: A total of 4 disulfidptosis-related lncRNAs (GIHCG, MKLN1-AS, AL031985.3, AL442125.2) were obtained and prognostic models were developed, and we found that patients in the high-risk group had worse overall survival (OS). ssGSEA analysis showed a positive correlation between immune cell infiltration and risk score. Low-risk patients were sensitive to gefitinib and high-risk patients were sensitive to bleomycin, gemcitabine, cisplatin, and etoposide. Cluster analysis identified two distinct subtypes with different prognoses and immune infiltration. This helps us to identify more precise targeted therapies for HCC patients. Conclusions: We established a disulfidptosis-related lncRNA model that can be exploited to predict the prognosis, tumor mutational burden, immune cell infiltration landscape, and response to drug therapy in HCC patients.
| [1] | Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [2] | Reig, M., Forner, A., Rimola, J., et al. (2022) BCLC Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 Update. Journal of Hepatology, 76, 681-693. https://doi.org/10.1016/j.jhep.2021.11.018 |
| [3] | Anwanwan, D., Singh, S.K., Singh, S., et al. (2020) Challenges in Liver Cancer and Possible Treatment Approaches. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1873, Article 188314. https://doi.org/10.1016/j.bbcan.2019.188314 |
| [4] | Zhao, J., Zhu, X.C., Wu, X.S., et al. (2020) Identification of miR-4644 as a Suitable Endogenous Normalizer for Circulating miRNA Quantification in Hepatocellular Carcinoma. Journal of Cancer, 11, 7032-7044. https://doi.org/10.7150/jca.48903 |
| [5] | Benson, A.B., D’Angelica, M.I., Abbott, D.E., et al. (2021) Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19, 541-565. https://doi.org/10.6004/jnccn.2021.0022 |
| [6] | Johnson, P., Zhou, Q., Dao, D.Y., et al. (2022) Circulating Biomarkers in the Diagnosis and Management of Hepatocellular Carcinoma. Nature Reviews Gastroenterology & Hepatology, 19, 670-681. https://doi.org/10.1038/s41575-022-00620-y |
| [7] | Lawson, K.A., Sousa, C.M., Zhang, X., et al. (2020) Functional Genomic Landscape of Cancer-Intrinsic Evasion of Killing by T cells. Nature, 586, 120-126. https://doi.org/10.1038/s41586-020-2746-2 |
| [8] | Tong, X., Tang, R., Xiao, M., et al. (2022) Targeting Cell Death Pathways for Cancer Therapy: Recent Developments in Necroptosis, Pyroptosis, Ferroptosis, and Cuproptosis Research. Journal of Hematology & Oncology, 15, Article No. 174. https://doi.org/10.1186/s13045-022-01392-3 |
| [9] | Peng, F., Liao, M., Qin, R., et al. (2022) Regulated Cell Death (RCD) in Cancer: Key Pathways and Targeted Therapies. Signal Transduction and Targeted Therapy, 7, Article No. 286. https://doi.org/10.1038/s41392-022-01110-y |
| [10] | Liu, X., Nie, L., Zhang, Y., et al. (2023) Actin Cytoskeleton Vulnerability to Disulfide Stress Mediates Disulfidptosis. Nature Cell Biology, 25, 404-414. https://doi.org/10.1038/s41556-023-01091-2 |
| [11] | Simion, V., Zhou, H., Haemmig, S., et al. (2020) A Macrophage-Specific lncRNA Regulates Apoptosis and Atherosclerosis by Tethering HuR in the Nucleus. Nature Communications, 11, Article No. 6135. https://doi.org/10.1038/s41467-020-19664-2 |
| [12] | Liu, Q., Huang, J., Zhou, N., et al. (2013) LncRNA loc285194 Is a p53-Regulated Tumor Suppressor. Nucleic Acids Research, 41, 4976-4987. https://doi.org/10.1093/nar/gkt182 |
| [13] | Hu, Q., Ye, Y., Chan, L.C., et al. (2019) Oncogenic lncRNA Downregulates Cancer Cell Antigen Presentation and Intrinsic Tumor Suppression. Nature Immunology, 20, 835-851. https://doi.org/10.1038/s41590-019-0400-7 |
| [14] | Marín-Béjar, O., Mas, A.M., González, J., et al. (2017) The Human lncRNA LINC-PINT Inhibits Tumor Cell Invasion through a Highly Conserved Sequence Element. Genome Biology, 18, Article No. 202. https://doi.org/10.1186/s13059-017-1331-y |
| [15] | Liang, Y.L., Zhang, Y., Tan, X.R., et al. (2022) A lncRNA Signature Associated with Tumor Immune Heterogeneity Predicts Distant Metastasis in Locoregionally Advanced Nasopharyngeal Carcinoma. Nature Communications, 13, Article No. 2996. https://doi.org/10.1038/s41467-022-30709-6 |
| [16] | Wu, Z.H., Li, Z.W., Yang, D.L., et al. (2021) Development and Validation of a Pyroptosis-Related Long Non-Coding RNA Signature for Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 9, Article 713925. https://doi.org/10.3389/fcell.2021.713925 |
| [17] | Bhan, A., Soleimani, M. and Mandal, S.S. (2017) Long Noncoding RNA and Cancer: A New Paradigm. Cancer Research, 77, 3965-3981. https://doi.org/10.1158/0008-5472.CAN-16-2634 |
| [18] | Ge, Y., Yan, X., Jin, Y., et al. (2015) fMiRNA-192 and miRNA-204 Directly Suppress lncRNA HOTTIP and Interrupt GLS1-Mediated Glutaminolysis in Hepatocellular Carcinoma. PLOS Genetics, 11, e1005726. https://doi.org/10.1371/journal.pgen.1005726 |
| [19] | Wang, H., Zhou, X., Li, C., et al. (2022) The Emerging Role of Pyroptosis in Pediatric Cancers: From Mechanism to Therapy. Journal of Hematology & Oncology, 15, Article No. 140. https://doi.org/10.1186/s13045-022-01365-6 |
| [20] | Zhang, G., Sun, J. and Zhang, X. (2022) A Novel Cuproptosis-Related LncRNA Signature to Predict Prognosis in Hepatocellular Carcinoma. Scientific Reports, 12, Article No. 11325. https://doi.org/10.1038/s41598-022-15251-1 |
| [21] | Xu, Z., Peng, B., Liang, Q., et al. (2021) Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma. Frontiers in Immunology, 12, Article 719175. https://doi.org/10.3389/fimmu.2021.719175 |
| [22] | Chen, X., Ye, Q., Chen, Z., et al. (2022) Long Non-Coding RNA Muskelin 1 Antisense RNA as a Potential Therapeutic Target in Hepatocellular Carcinoma Treatment. Bioengineered, 13, 12237-12247. https://doi.org/10.1080/21655979.2022.2074703 |
| [23] | Lu, F., Song, Y., Cui, S., et al. (2021) LncRNA MIAT Promotes the Proliferation, Migration, and Invasion of Melanoma Cells through Recruiting TCF12 and Activating NFAT5. American Journal of Translational Research, 13, 12588-12600. |
| [24] | Xiao, S., Huang, S. and Yang, J. (2020) Overexpression of GIHCG Is Associated with a Poor Prognosis and Immune Infiltration in Hepatocellular Carcinoma. OncoTargets and Therapy, 13, 11607-11619. https://doi.org/10.2147/OTT.S271966 |
| [25] | Sui, C.J., Zhou, Y.M., Shen, W.F., et al. (2016) Long Noncoding RNA GIHCG Promotes Hepatocellular Carcinoma Progression through Epigenetically Regulating miR-200b/a/429. Journal of Molecular Medicine, 94, 1281-1296. https://doi.org/10.1007/s00109-016-1442-z |
| [26] | Xiang, Z., Song, S., Zhu, Z., et al. (2019) LncRNAs GIHCG and SPINT1-AS1 Are Crucial Factors for Pan-Cancer Cells Sensitivity to Lapatinib. Frontiers in Genetics, 10, Article 25. https://doi.org/10.3389/fgene.2019.00025 |
| [27] | Zhou, P., Lu, Y., Zhang, Y., et al. (2021) Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients with Hepatocellular Carcinoma. Frontiers in Oncology, 11, Article 661758. https://doi.org/10.3389/fonc.2021.661758 |
| [28] | Chen, M., Wu, G.B., Hua, S., et al. (2022) Identification and Validation of a Prognostic Model of Necroptosis-Related lncRNAs in Hepatocellular Carcinoma. Frontiers in Genetics, 13, Article 907859. https://doi.org/10.3389/fgene.2022.907859 |
| [29] | Zhu, L., Zhang, X.P., Xu, S., et al. (2022) Identification of a CD4 Conventional T Cells-Related lncRNAs Signature Associated with Hepatocellular Carcinoma Prognosis, Therapy, and Tumor Microenvironment. Frontiers in Immunology, 13, Article 1111246. https://doi.org/10.3389/fimmu.2022.1111246 |
| [30] | Chen, Z.A., Tian, H., Yao, D.M., et al. (2021) Identification of a Ferroptosis-Related Signature Model Including mRNAs and lncRNAs for Predicting Prognosis and Immune Activity in Hepatocellular Carcinoma. Frontiers in Oncology, 11, Article 738477. https://doi.org/10.3389/fonc.2021.738477 |
| [31] | Xia, X., Zhang, H., Xia, P., et al. (2021) Identification of Glycolysis-Related lncRNAs and the Novel lncRNA WAC-AS1 Promotes Glycolysis and Tumor Progression in Hepatocellular Carcinoma. Frontiers in Oncology, 11, Article 733595. https://doi.org/10.3389/fonc.2021.733595 |
